David Grimwade

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi request reprint Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    David Grimwade
    Cancer Genetics Lab, Department of Medical and Molecular Genetics, King s College London School of Medicine, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, UK Electronic address
    Best Pract Res Clin Haematol 27:53-61. 2014
  2. pmc Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia
    Jelena V Jovanovic
    Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, King s College London School of Medicine London, UK
    Front Oncol 1:35. 2011
  3. pmc Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902)
    J V Jovanovic
    King s College London School of Medicine, Cancer Genetics Lab, Department of Medical and Molecular Genetics, London, UK
    Leukemia 27:2032-9. 2013
  4. pmc Molecular pathogenesis of secondary acute promyelocytic leukemia
    M Joannides
    Department of Medical and Molecular Genetics, King s College London School of Medicine, UK
    Mediterr J Hematol Infect Dis 3:e2011045. 2011
  5. doi request reprint Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia
    David Grimwade
    Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, Guy s Hospital, King s College London School of Medicine, 8th Floor, Guy s Tower, London SE1 9RT, UK
    Hematol Oncol Clin North Am 25:1135-61, vii. 2011
  6. doi request reprint The changing paradigm of prognostic factors in acute myeloid leukaemia
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine, UK
    Best Pract Res Clin Haematol 25:419-25. 2012
  7. doi request reprint Assessment of minimal residual disease in acute myeloid leukemia
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s and St Thomas NHS Foundation Trust, London, UK
    Curr Opin Oncol 22:656-63. 2010
  8. ncbi request reprint Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine and Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, United Kingdom
    Blood 116:354-65. 2010
  9. doi request reprint Acute promyelocytic leukemia: a paradigm for differentiation therapy
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
    Cancer Treat Res 145:219-35. 2010
  10. ncbi request reprint Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
    David Grimwade
    Dept of Medical and Molecular Genetics, King s College London School of Medicine, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, United Kingdom
    J Clin Oncol 27:3650-8. 2009

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    David Grimwade
    Cancer Genetics Lab, Department of Medical and Molecular Genetics, King s College London School of Medicine, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, UK Electronic address
    Best Pract Res Clin Haematol 27:53-61. 2014
    ....
  2. pmc Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia
    Jelena V Jovanovic
    Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, King s College London School of Medicine London, UK
    Front Oncol 1:35. 2011
    ..These data highlight the potential of RT-qPCR detection of MRD to facilitate development of more individualized approaches to the management of rarer molecularly defined subsets of acute leukemia...
  3. pmc Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902)
    J V Jovanovic
    King s College London School of Medicine, Cancer Genetics Lab, Department of Medical and Molecular Genetics, London, UK
    Leukemia 27:2032-9. 2013
    ..This study has established a robust, reliable assay for sensitive JAK2-V617F detection, suitable for assessing response in clinical trials, predicting outcome and guiding management of patients undergoing allogeneic transplant...
  4. pmc Molecular pathogenesis of secondary acute promyelocytic leukemia
    M Joannides
    Department of Medical and Molecular Genetics, King s College London School of Medicine, UK
    Mediterr J Hematol Infect Dis 3:e2011045. 2011
    ..The observation that particular regions of the PML and RARA loci are susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie the propensity of these agents to cause APL...
  5. doi request reprint Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia
    David Grimwade
    Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, Guy s Hospital, King s College London School of Medicine, 8th Floor, Guy s Tower, London SE1 9RT, UK
    Hematol Oncol Clin North Am 25:1135-61, vii. 2011
    ..Cytogenetics has been widely adopted to provide the framework for development of risk-stratified treatment approaches to patient management...
  6. doi request reprint The changing paradigm of prognostic factors in acute myeloid leukaemia
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine, UK
    Best Pract Res Clin Haematol 25:419-25. 2012
    ....
  7. doi request reprint Assessment of minimal residual disease in acute myeloid leukemia
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s and St Thomas NHS Foundation Trust, London, UK
    Curr Opin Oncol 22:656-63. 2010
    ..We review recent studies highlighting the potential for novel and standardized assays to provide independent prognostic information and develop more personalized treatment approaches...
  8. ncbi request reprint Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine and Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, United Kingdom
    Blood 116:354-65. 2010
    ..This study is registered at http://www.isrctn.org as ISRCTN55678797 and ISRCTN17161961...
  9. doi request reprint Acute promyelocytic leukemia: a paradigm for differentiation therapy
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
    Cancer Treat Res 145:219-35. 2010
    ..This represents an exciting new phase in the treatment of acute leukemia, highlighting the potential of molecularly targeted and MRD-directed therapies to achieve an individualized approach to patient management...
  10. ncbi request reprint Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
    David Grimwade
    Dept of Medical and Molecular Genetics, King s College London School of Medicine, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, United Kingdom
    J Clin Oncol 27:3650-8. 2009
    ....
  11. pmc Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia
    Ashley N Mays
    Department of Medical and Molecular Genetics, King s College London School of Medicine, London, United Kingdom
    Blood 115:326-30. 2010
    ....
  12. pmc The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells
    William Puszyk
    Department of Medical and Molecular Genetics, King s College London, London, UK
    EMBO J 32:1941-52. 2013
    ..These results reveal a novel mechanism of action by which, PLZF represses retrotransposons, safeguarding normal progenitor homeostasis. ..
  13. ncbi request reprint Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    Jelena V Jovanovic
    Department of Medical and Molecular Genetics, Guy s Hospital, King s College London, UK
    Blood 109:4635-40. 2007
    ....
  14. ncbi request reprint Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML
    Rajinder Flora
    Guy s, King s, and St Thomas School of Medicine, London, UK
    Methods Mol Med 91:151-73. 2004
  15. pmc RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia
    Fabien Guidez
    Department of Medical and Molecular Genetics, King s College London, Guy s Hospital, London SE1 9RT, United Kingdom
    Proc Natl Acad Sci U S A 104:18694-9. 2007
    ....
  16. ncbi request reprint The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease
    Anita R Mistry
    Division of Medical and Molecular Genetics, Guy s, King s and St Thomas School of Medicine, London, UK
    Blood Rev 17:71-97. 2003
    ....
  17. ncbi request reprint DNA topoisomerase II in therapy-related acute promyelocytic leukemia
    Anita R Mistry
    Department of Medical and Molecular Genetics, Guy s, King s, and St Thomas School of Medicine, London
    N Engl J Med 352:1529-38. 2005
    ..We studied acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or laryngeal cancer with chemotherapeutic agents that poison topoisomerase II...
  18. ncbi request reprint The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells
    David Grimwade
    Division of Medical and Molecular Genetics, Guy s, King s and St Thomas School of Medicine, London SE1 9RT, UK
    Cancer Res 62:4730-5. 2002
    ..The demonstration of T-cell-associated chromatin features in primary APL blasts has implications for the origin of APL that may arise in more primitive progenitors than previously considered to be the case...
  19. ncbi request reprint PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?
    Nicola J M Brown
    Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
    Front Biosci (Landmark Ed) 14:1684-707. 2009
    ....
  20. ncbi request reprint Molecular biology of therapy-related leukaemias
    Melanie Joannides
    Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s Hospital, London, UK
    Clin Transl Oncol 12:8-14. 2010
    ..Although treatment of therapy-related leukaemias represents a considerable challenge due to prior therapy and comorbidities, curative therapy is possible, particularly in those with favourable karyotypic features...
  21. ncbi request reprint Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia
    Letizia Foroni
    Department of Haematology, Imperial College Academic Health Science Centre, Hammersmith Hospital, Du Cane Rd, London, UK
    Br J Haematol 153:179-90. 2011
    ....
  22. ncbi request reprint The significance of minimal residual disease in patients with t(15;17)
    David Grimwade
    Division of Medical and Molecular Genetics, Guy s, King s and St Thomas School of Medicine, Cancer Genetics Laboratory, 8th Floor, Guy s Tower, Guy s Hospital, London SE1 9RT, UK
    Best Pract Res Clin Haematol 15:137-58. 2002
    ....
  23. doi request reprint Independent prognostic variables in acute myeloid leukaemia
    Matthew L Smith
    Department of Haematology, St Bartholomew s Hospital, London, UK
    Blood Rev 25:39-51. 2011
    ....
  24. ncbi request reprint Molecular markers in acute myeloid leukaemia
    Andrea Kühnl
    Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
    Int J Hematol 96:153-63. 2012
    ..Finally, molecular markers are important for the detection of minimal residual disease after initial therapy and during long-term follow-up, which enables a more tailored treatment approach for individual AML patients...
  25. doi request reprint Mutation of the RAD51C gene in a Fanconi anemia-like disorder
    Fiona Vaz
    Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s Hospital, London, UK
    Nat Genet 42:406-9. 2010
    ..Thus, biallelic germline mutations in a RAD51 paralog are associated with an FA-like syndrome...